Showing results (311-320 of 376) with videos related to

Sort By:
Pageof 38
Plos Genetics|August 8, 2014
Dysfunction of the CNS-heart axis in mouse models of Huntington's diseaseMichal Mielcarek, Linda Inuabasi, Marie K Bondulich, et al.
Neurobiology of Disease|June 1, 2011
Gastrointestinal dysfunction contributes to weight loss in Huntington's disease miceJorien M M van der Burg, Annika Winqvist, N Ahmad Aziz, et al.
Chemistry & Biology|February 28, 2012
TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's diseaseBarbara Baldo, Paolo Paganetti, Stephan Grueninger, et al.
Human Molecular Genetics|March 1, 1993
The isolation of cDNAs within the Huntington disease region by hybridisation of yeast artificial chromosomes to a cDNA libraryR G Snell, L A Doucette-Stamm, K M Gillespie, et al.
EMBO Reports|October 11, 2024
m6A modification of mutant huntingtin RNA promotes the biogenesis of pathogenic huntingtin transcriptsAnika Pupak, Irene Rodríguez-Navarro, Kirupa Sathasivam, et al.
ACS Chemical Biology|March 5, 2011
A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylaseDavid M Taylor, Uma Balabadra, Zhongmin Xiang, et al.
The Journal of Biological Chemistry|January 21, 2010
Proteolysis of mutant huntingtin produces an exon 1 fragment that accumulates as an aggregated protein in neuronal nuclei in Huntington diseaseChristian Landles, Kirupa Sathasivam, Andreas Weiss, et al.
Human Molecular Genetics|February 12, 2010
CalDAG-GEFI down-regulation in the striatum as a neuroprotective change in Huntington's diseaseJill R Crittenden, Denise E Dunn, Farhan I Merali, et al.
Neurobiology of Disease|December 18, 2003
Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylationRuth Luthi-Carter, Barbara L Apostol, Anthone W Dunah, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 6, 1999
A phase II study of the modulation of 5-fluorouracil and folinic acid with high-dose infusional hydroxyurea in metastatic colorectal carcinomaK J O'Byrne, P A Philip, D J Propper, et al.
Pageof 38